- Home
- CORT
as 07-26-2024 4:00pm EST
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Upcoming Earnings Alert:
Get ready for potential market movements as Corcept Therapeutics Incorporated CORT prepares to release earnings report on 29 Jul 2024.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 3.5B | IPO Year: | N/A |
| Target Price: | $41.40 | AVG Volume (30 days): | 837.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.06 | EPS Growth: | 29.27 |
| 52 Week Low/High: | $20.84 - $35.94 | Next Earning Date: | 07-29-2024 |
| Revenue: | $523,529,000 | Revenue Growth: | 26.51% |
| Revenue Growth (this year): | 33.67% | Revenue Growth (next year): | 13.21% |
Stock Insider Trading Activity of Corcept Therapeutics Incorporated (CORT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Swisher Daniel N JR | CORT | Director | Jul 1 '24 | Sell | $32.81 | 2,200 | $72,182.00 | 0 | SEC Form 4 |
| Robb Gary Charles | CORT | Chief Business Officer | Jul 1 '24 | Sell | $32.49 | 11,000 | $357,390.00 | 26,291 | SEC Form 4 |
| Guyer William | CORT | Chief Development Officer | Jul 1 '24 | Sell | $32.49 | 10,000 | $324,900.00 | 6,039 | SEC Form 4 |
| Lyon Joseph Douglas | CORT | See Remarks | Jul 1 '24 | Sell | $32.49 | 5,000 | $162,452.00 | 9,290 | SEC Form 4 |
| Guyer William | CORT | Chief Development Officer | Jun 3 '24 | Sell | $32.00 | 10,000 | $320,000.00 | 6,039 | SEC Form 4 |
| Lyon Joseph Douglas | CORT | See Remarks | Jun 3 '24 | Sell | $30.18 | 5,000 | $150,916.00 | 7,314 | SEC Form 4 |
| Robb Gary Charles | CORT | Chief Business Officer | May 28 '24 | Sell | $30.39 | 11,000 | $334,294.40 | 20,203 | SEC Form 4 |
| Guyer William | CORT | Chief Development Officer | May 28 '24 | Sell | $32.00 | 30,000 | $960,000.00 | 6,039 | SEC Form 4 |
| Maduck Sean | CORT | See Remarks | May 13 '24 | Sell | $28.00 | 50,000 | $1,400,000.00 | 85,222 | SEC Form 4 |
| Lyon Joseph Douglas | CORT | See Remarks | May 9 '24 | Sell | $26.00 | 7,227 | $187,902.00 | 7,314 | SEC Form 4 |
| Lyon Joseph Douglas | CORT | See Remarks | May 2 '24 | Sell | $26.00 | 10,830 | $281,580.00 | 7,314 | SEC Form 4 |
| Swisher Daniel N JR | CORT | Director | May 1 '24 | Sell | $23.09 | 2,200 | $50,798.00 | 0 | SEC Form 4 |
| Lyon Joseph Douglas | CORT | See Remarks | Apr 4 '24 | Sell | $26.00 | 5,443 | $141,523.99 | 7,314 | SEC Form 4 |
| Lyon Joseph Douglas | CORT | See Remarks | Apr 1 '24 | Sell | $26.01 | 500 | $13,003.50 | 7,314 | SEC Form 4 |
| Swisher Daniel N JR | CORT | Director | Apr 1 '24 | Sell | $25.30 | 2,200 | $55,660.00 | 0 | SEC Form 4 |
| Maduck Sean | CORT | See Remarks | Mar 27 '24 | Sell | $25.01 | 25,953 | $649,024.84 | 85,222 | SEC Form 4 |
| Maduck Sean | CORT | See Remarks | Mar 18 '24 | Sell | $25.00 | 17,219 | $430,475.00 | 75,222 | SEC Form 4 |
| Swisher Daniel N JR | CORT | Director | Mar 1 '24 | Sell | $23.59 | 2,200 | $51,898.00 | 0 | SEC Form 4 |
| Lyon Joseph Douglas | CORT | Chief Accounting Officer | Feb 16 '24 | Sell | $26.00 | 1,000 | $26,000.00 | 6,774 | SEC Form 4 |
| Maduck Sean | CORT | See Remarks | Feb 15 '24 | Sell | $25.00 | 4,760 | $119,000.00 | 74,455 | SEC Form 4 |
| Maduck Sean | CORT | See Remarks | Feb 15 '24 | Sell | $25.97 | 27,068 | $702,904.53 | 74,455 | SEC Form 4 |
| Swisher Daniel N JR | CORT | Director | Feb 1 '24 | Sell | $22.00 | 2,200 | $48,400.00 | 0 | SEC Form 4 |
| Swisher Daniel N JR | CORT | Director | Jan 2 '24 | Sell | $22.11 | 2,200 | $48,642.00 | 0 | SEC Form 4 |
| Guyer William | CORT | Chief Development Officer | Dec 22 '23 | Sell | $32.00 | 10,000 | $320,000.00 | 6,643 | SEC Form 4 |
| Robb Gary Charles | CORT | Chief Business Officer | Dec 4 '23 | Sell | $26.27 | 1,381 | $36,277.21 | 27,602 | SEC Form 4 |
Latest Corcept Therapeutics Incorporated News
CORT Breaking Stock News: Dive into CORT Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
CORT: Raising target price to $36.00
GlobeNewswire
4 days ago
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Zacks
8 days ago
Navigate Market Turbulence With These 4 Low-Beta Stocks
Zacks
9 days ago
Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics
Argus Research
10 days ago
CORT: Raising target price to $35.00
Zacks
10 days ago
What Makes Corcept (CORT) a Good Fit for 'Trend Investing'
Simply Wall St.
16 days ago
High Insider Ownership Growth Companies On US Exchanges In July 2024
Argus Research
17 days ago
CORT: Lowering target price to $31.00
Compare CORT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CORT Corcept Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.